Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination of mirabegron and bisoprolol**. Mirabegron is a **selective beta-3 adrenergic receptor agonist** primarily used to treat overactive bladder by relaxing detrusor smooth muscle during bladder filling, increasing bladder capacity and decreasing episodes of urge incontinence, urgency, and frequency. Bisoprolol is a **selective beta-1 adrenergic receptor antagonist (beta-blocker)** commonly used for hypertension and cardiac conditions by decreasing heart rate and cardiac output. When combined, bisoprolol can mitigate the cardiovascular side effects of mirabegron (such as increased heart rate and blood pressure); however, it may also blunt mirabegron’s effects on brown adipose tissue thermogenesis, lipolysis, and glucose uptake. This combination is **not a standard approved fixed-dose pharmaceutical product** but has been studied for research purposes, particularly to separate the metabolic effects of mirabegron from its cardiovascular effects[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mirabegron + bisoprolol.